VIVUS (VVUS) Lower; Data Shows Unexpected Drop in Qsymia Prescriptions for Week 6 - BI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
VIVUS (VVUS) Qsymia Prescriptions Now Said to Be Up 25% in Week 6, In-Line with Views
November 5, 2012 12:31 PM ESTVIVUS (Nasdaq: VVUS) is now higher on the session heading into its third-quarter earnings report tomorrow, as new Qsymia data for week 6 prescriptions surfaces.
... More
Latest Qsymia Data Shapes Up Potential Bear Case for VIVUS (VVUS) and Peers (ARNA) (OREX)
October 31, 2012 2:18 PM EDTVIVUS (Nasdaq: VVUS) shares continue to be pressured Wednesday amid a note that its obesity pill may have fad-like qualities.
Cowen's Simos Simeonidis said today that the latest data out of IMS and Wolters Kluwer suggest that Qsymia, as well as other... More
